Overview
Updated 14 Jul 2026
Rachel Sanborn, MD, is Co-Director, Thoracic Oncology Program at Earle A. Chiles Research Institute, Providence Cancer Institute (Providence Cancer Center), Portland, OR. The public record shows 301 publications with 9,353 citations (h-index 39), centered on Lung Cancer (NSCLC/SCLC), Kidney Cancer / RCC. It also documents an investigator role on 13 registered clinical trials, industry payments reported by 23 companies.
- Most recent indexed publication: 2026 · Journal of clinical oncology
- Top research focus: Lung Cancer (NSCLC/SCLC)
- 13 registered trials on ClinicalTrials.gov
- Open Payments reporting from 23 companies
Generated from the cited public record · current as of 14 Jul 2026. Every fact links its source below.
Indications focusfrom trials led + research topics
Research focusOpenAlex concept fingerprint
Drugs & moleculesacross trials, industry payments and publications
Works withtrial sponsors and companies reporting payments
Scholarshipindexed output and impact (OpenAlex)
View publications ↓Distinct works indexed by OpenAlex, matched via ORCID; 22 in PubMed.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industrytrials, payments and federal funding
Federally funded research awards.
Clinical trials
Updated 14 Jul 2026
Listed as an investigator on 13 registered studies on ClinicalTrials.gov. The most recent:
- Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors
Sponsor: SystImmune Inc.
InvestigatorPhase 1RecruitingNCT07080242 - Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
Sponsor: Eli Lilly and Company
InvestigatorPhase 3RecruitingNCT06890598 - Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
Sponsor: SystImmune Inc.
InvestigatorPhase 1RecruitingNCT06293898
Industry payments
Updated 14 Jul 2026
23 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Merck Sharp & Dohme LLCProgram year20258 payments$10,547openpaymentsdata.cms.gov ↗
- Janssen Biotech, Inc.Program year20257 payments$10,534openpaymentsdata.cms.gov ↗
- PFIZER INC.Program year20254 payments
NIH funding
We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →
Publications
Updated 14 Jul 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Phase 1 Study of INBRX-105, a TNFRSF9 (4-1BB) and PD-L1 Bispecific Antibody, in Patients with Select Solid Tumors.
Cancer research communications
2026 - Efficacy and safety of garsorasib in patients with KRAS G12C-mutated advanced pancreatic cancer.
British journal of cancer
2026
Contact
An office address from a public listing. This research profile has no federal registry record to draw from.
Office address
4805 NE Glisan St, Suite 11N-1, Portland, OR 97213
Background & recognition
Updated 14 Jul 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Educationdegrees and training on record
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →providence.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →providence.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →providence.org ↗
- Board Certified
Internal Medicine (American Board of Internal Medicine)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →providence.org ↗ - Board Certified
Medical Oncology
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →providence.org ↗ - BA
Cornell College
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →lung.org ↗
Editorial & leadership rolesjournal and society appointments
- Co-Director
Thoracic Oncology Program, Earle A. Chiles Research Institute, Providence Cancer Institute
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →pub.orcid.org ↗ - Leader (Director)
Phase I Clinical Trials Program, Earle A. Chiles Research Institute
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →pub.orcid.org ↗ - Member
Providence Health & Services Institutional Review Board
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →providence.org ↗
Awards & honorshonors on the public record
- 2024 American Lung Association of the Pacific Northwest Breathe Easy Gala Honoree
recognized for efforts to improve lung cancer outcomes, reduce stigma, enable earlier detection, and reduce lung cancer incidence
2024verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →foundation.providence.org ↗
Secondary affiliationsappointments beyond the home institution
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →providence.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →providence.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →providence.org ↗
Media & interviewspress, podcasts and appearances
- GRACE (Global Resource for Advancing Cancer Education) Faculty
recurring video contributor on lung cancer topics (e.g. "Basics of Small Cell Lung Cancer")
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →cancergrace.org ↗ - Video interview: "Rachel E. Sanborn, MD, on NSCLC: Maximizing the Benefits of Targeted Therapies for EGFR-Mutated Disease"
The ASCO Post, ASCO20 Virtual Scientific Program
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ascopost.com ↗ - Video contributor
Targeted Oncology, "Sanborn Covers Recently Presented Trials Supporting Immunotherapy in Frontline NSCLC" (live case-based peer perspectives)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →targetedonc.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Online presence
Updated 14 Jul 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accountspublic accounts run by this person
- Doximity
doximity.com/pub/rachel-sanborn-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - LinkedIn
linkedin.com/in/rachel-sanborn-md-0583ab304
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗ - X / Twitter
x.com/rachelsanbornmd
Mentions by otherswhere others cite or feature them
- Other
foundation.providence.org/oregon/portland/about-us/news-stories/dr-rachel-sanborn-honored-by-the-american-lung-association-leads-clinical-trials-that-result-in-drug-approval-and-new-hope-for-patients
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →foundation.providence.org ↗ - X / Twitter
x.com/ChilesResearch
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Pasi Janne, MD, PhD
Harvard University
- 2,385
- publications
- 163
- h-index
- 15
- trials
Julie Brahmer, MD
Bloomberg (United States)
- 855
- publications
- 116
- h-index
- 12
- trials
Enriqueta Felip, MD, PhD
Hebron University
- 1,460
- publications
- 129
- h-index
- 8
- trials
Funda Meric-Bernstam, MD
The University of Texas MD Anderson Cancer Center
- 2,643
- publications
- 148
- h-index
- 8
- trials